TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Goldman Sachs 47th Annual Healthcare Conference at the Loews Miami Beach Hotel in Florida from June 8-10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 PM ET, with a live webcast available on the Events page in the Investors & Media section of the company website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TGTX
-2.06%
40 alerts
-2.06%Session close to close
+7.8%Peak in 5 hr 55 min
$6.32BMarket Cap
0.9xRel. Volume
In the Jun 2 session, TGTX declined 2.06%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +7.8% during that session.
Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility.
This announcement highlights TG Therapeutics’ participation in a major Goldman Sachs healthcare conf...
Analysis
This announcement highlights TG Therapeutics’ participation in a major Goldman Sachs healthcare conference, continuing a series of visibility events following strong BRIUMVI data and Q1 2026 revenue of $204.9 million. Investors may track how management discusses updated revenue guidance of about $925 million, capital structure including the $750 million term loan, and potential use of its effective S-3ASR shelf, alongside progress toward planned regulatory submissions.
Key Figures
Q1 2026 revenue:$204.9MBRIUMVI revenue:$201.3MNet income:$19.8M+5 more
8 metrics
Q1 2026 revenue$204.9MQuarter ended March 31, 2026 (10-Q/8-K)
Q1 2026 results, higher BRIUMVI guidance, non-dilutive capital and buybacks.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent fundamentally positive clinical and earnings updates have sometimes seen negative next-day moves, while major guidance raises drew a strong positive reaction.
Recent Company History
Over the past few months, TG Therapeutics has focused on strengthening its BRIUMVI franchise and financial profile. Positive Phase 3 ENHANCE topline data on May 27, 2026 and post‑hoc ULTIMATE I & II results on June 1, 2026 highlighted clinical momentum, yet were followed by modest share declines. In contrast, Q1 2026 results on May 6, 2026 with raised revenue guidance and non‑dilutive financing drove a 16.26% gain. Conference participation news on May 28 saw a small pullback, similar in nature to today’s Goldman Sachs conference announcement.
Key Terms
form s-3 shelf registration, term loan, term sofr, schedule 13g, +4 more
8 terms
form s-3 shelf registrationregulatory
"filed a Form S-3 shelf registration as a well-known seasoned issuer"
A Form S-3 shelf registration is a streamlined U.S. Securities and Exchange Commission filing that lets an eligible, regularly reporting company register a pool of securities ahead of time and sell them later as needed. Think of it like putting items on a store shelf so the company can quickly offer shares or debt when an opportunity or need arises; for investors it signals regulatory compliance and readiness to raise capital, but also means potential future dilution or changes in ownership.
term loanfinancial
"creates a new $750 million 2026 term loan, which was fully drawn"
A term loan is a type of loan that is borrowed for a set period of time, with a fixed schedule for repaying the money, usually in regular payments. It matters to investors because it represents a company's borrowing costs and financial stability; reliable repayment of these loans can indicate strong financial health, while difficulties may signal potential risks.
term sofrfinancial
"carries a variable interest rate based on either a base rate or Term SOFR"
Term SOFR is a benchmark interest rate that reflects the cost of borrowing money over a specific period, based on actual transactions in the financial markets. It is used by lenders and borrowers to set the interest rates on loans and financial contracts, helping to ensure rates are fair and transparent. For investors, understanding term SOFR helps gauge borrowing costs and the overall direction of interest rates in the economy.
schedule 13gregulatory
"reported a passive Schedule 13G ownership filing by Vanguard"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
schedule 13g/aregulatory
"filed Amendment No. 6 to a Schedule 13G/A reporting 0 shares"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
definitive proxy statementregulatory
"DEF 14A] TG THERAPEUTICS, INC. Definitive Proxy Statement"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
biologics license applicationregulatory
"targeting submission of a supplemental biologics license application in the second half"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
restricted stockfinancial
"includes shares of restricted stock that vest over various time periods"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026. The fireside chat is scheduled to take place on Tuesday, June 9, 2026, at 2:00 PM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at https://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When will TG Therapeutics (TGTX) present at the Goldman Sachs 47th Annual Healthcare Conference?
TG Therapeutics will participate in a fireside chat on Tuesday, June 9, 2026, at 2:00 PM ET. The session is part of the Goldman Sachs 47th Annual Healthcare Conference held June 8-10, 2026, in Miami Beach, Florida.
Who is representing TG Therapeutics (TGTX) at the Goldman Sachs healthcare conference in June 2026?
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, will represent the company at the conference. He is scheduled for a fireside chat on June 9, 2026, at 2:00 PM ET.
How can investors watch TG Therapeutics’ June 9, 2026 fireside chat at the Goldman Sachs conference?
Investors can watch the fireside chat via a live webcast available on TG Therapeutics’ website. According to the company, it will be hosted on the Events page in the Investors & Media section.
Where is the Goldman Sachs 47th Annual Healthcare Conference featuring TG Therapeutics (TGTX) being held?
The conference is being held at the Loews Miami Beach Hotel in Miami Beach, Florida. TG Therapeutics’ fireside chat with Michael S. Weiss is scheduled there for June 9, 2026, at 2:00 PM ET.
What are the dates of the Goldman Sachs 47th Annual Healthcare Conference attended by TG Therapeutics (TGTX)?
The Goldman Sachs 47th Annual Healthcare Conference runs from June 8 to June 10, 2026. TG Therapeutics is participating, with a scheduled fireside chat on June 9, 2026, at 2:00 PM ET.
